Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ONCT

Oncternal Therapeutics Inc

May 16 • 12:33PM ET

8.66

Dollar change -0.18
Percentage change -2.04	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DFAT DFAS DFAC IWM IWO IWC ITOT IWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.34	Insider Own	9.78%	Shs Outstand	2.95M	Perf Week	0.29%
Market Cap	25.63M	Forward P/E	-	EPS next Y	-8.49	Insider Trans	3.58%	Shs Float	2.67M	Perf Month	-0.35%
Income	-36.38M	PEG	-	EPS next Q	-2.58	Inst Own	16.42%	Short Float	0.49%	Perf Quarter	-5.66%
Sales	1.15M	P/S	22.29	EPS this Y	24.68%	Inst Trans	-74.43%	Short Ratio	1.76	Perf Half Y	38.12%
Book/sh	7.75	P/B	1.12	EPS next Y	16.07%	ROA	-83.23%	Short Interest	0.01M	Perf Year	46.78%
Cash/sh	9.13	P/C	0.95	EPS next 5Y	0.00%	ROE	-96.48%	52W Range	5.57 - 13.14	Perf YTD	-19.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.19%	ROI	-158.00%	52W High	-34.09%	Beta	1.28
Dividend TTM	-	Quick Ratio	4.66	Sales past 5Y	-9.91%	Gross Margin	72.08%	52W Low	55.60%	ATR (14)	0.53
Dividend Ex-Date	-	Current Ratio	4.66	EPS Y/Y TTM	26.32%	Oper. Margin	-3331.89%	RSI (14)	50.43	Volatility	5.26% 5.94%
Employees	27	Debt/Eq	0.01	Sales Y/Y TTM	21.54%	Profit Margin	-3160.73%	Recom	1.50	Target Price	30.67
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	27.79%	Payout	-	Rel Volume	0.50	Prev Close	8.84
Sales Surprise	210.42%	EPS Surprise	1.65%	Sales Q/Q	180.30%	Earnings	May 09 AMC	Avg Volume	7.37K	Price	8.66
SMA20	0.97%	SMA50	-0.22%	SMA200	11.27%	Trades		Volume	1,815	Change	-2.04%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-21	Initiated	Oppenheimer	Outperform	$14
Feb-23-21	Initiated	Northland Capital	Outperform	$21

May-10-24 12:40PM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.28%
May-09-24 08:58PM	ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:20PM	Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-08-24 12:00PM	All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy (Zacks)
04:05PM	Loading…
May-02-24 04:05PM	Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results (GlobeNewswire) +6.00%
May-01-24 09:00AM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-25-24 10:02AM	Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-18-24 09:00AM	Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Apr-14-24 12:51PM	5 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 04:42PM	10 Underperforming Stocks Insiders are Buying (Insider Monkey)
Mar-15-24 09:00AM	Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer (GlobeNewswire)
Mar-08-24 10:26AM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:54PM	ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:05PM	Loading…
Feb-29-24 04:05PM	Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-06-24 04:30PM	Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-01-24 09:00AM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-24 09:00AM	Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) +5.08%
Jan-04-24 09:00AM	Oncternal Therapeutics Announces Reverse Stock Split (GlobeNewswire) -24.49%
Jan-02-24 09:00AM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-23 11:04AM	Oncternal Therapeutics reports patient death in CAR-T dose-escalation study (FierceBiotech.com) -12.42%
Dec-26-23 09:00AM	Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma (GlobeNewswire)
Nov-11-23 11:06AM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire) -9.07%
Nov-02-23 04:05PM	Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-26-23 09:00AM	Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Oct-25-23 09:00AM	Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (GlobeNewswire)
Oct-05-23 04:01PM	Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Sep-07-23 09:00AM	Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board (GlobeNewswire)
04:01PM	Loading…
Aug-10-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results (GlobeNewswire) -6.71%
Aug-03-23 04:30PM	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results (GlobeNewswire)
04:05PM	Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer (GlobeNewswire)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jun-30-23 04:30PM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-23 04:01PM	Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma (GlobeNewswire)
May-31-23 05:00PM	Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-06-23 08:14AM	Oncternal Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
May-04-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 05:00PM	Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results (GlobeNewswire) +6.62%
Apr-17-23 06:54AM	Daily Vickers Top Buyers & Sellers for 04/17/2023 (Argus Research) +14.57%
Apr-13-23 05:00PM	Oncternal Therapeutics Participating in Oppenheimer & Co.s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors (GlobeNewswire)
Apr-03-23 04:01PM	Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 (GlobeNewswire)
Mar-27-23 09:00AM	Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.39%
Mar-11-23 03:14AM	Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-02-23 05:00PM	Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-01-23 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-23 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-23 04:05PM	Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors (GlobeNewswire)
Jan-03-23 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-10-22 03:00PM	Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022 (GlobeNewswire)
Dec-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.21%
Nov-03-22 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results (GlobeNewswire)
09:05AM	Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022 (GlobeNewswire)
Oct-27-22 05:53PM	Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-03-22 05:30PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.80%
04:31PM	Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma (GlobeNewswire)
Sep-27-22 09:00AM	Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL (GlobeNewswire)
Sep-23-22 09:00AM	Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire)
Sep-07-22 05:00PM	Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 04:05PM	Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 05:00PM	Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-26-22 07:34AM	The past three years for Oncternal Therapeutics (NASDAQ:ONCT) investors has not been profitable (Simply Wall St.)
Jul-14-22 04:01PM	Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL (GlobeNewswire)
Jun-10-22 04:30PM	Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress (GlobeNewswire) -13.99%
09:00AM	Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress (GlobeNewswire)
Jun-02-22 09:00AM	Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022 (GlobeNewswire)
Jun-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.41%
May-26-22 05:15PM	Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022 (GlobeNewswire)
May-17-22 07:40AM	Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation (Simply Wall St.) +12.90%
May-05-22 04:01PM	Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results (GlobeNewswire)
May-02-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +23.05%
Apr-28-22 05:00PM	Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results (GlobeNewswire)
03:02PM	Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-13-22 08:30AM	Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma (GlobeNewswire)
Apr-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-10-22 04:01PM	Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-07-22 05:00PM	Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-01-22 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-22 10:11AM	Oncternal Therapeutics (NASDAQ:ONCT) investors are sitting on a loss of 75% if they invested a year ago (Simply Wall St.)
Jan-20-22 04:05PM	Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer (GlobeNewswire) -5.83%
Jan-19-22 05:38PM	Traverso Chambers Private Wealth Management, LLC Buys WisdomTree U.S. ... (GuruFocus.com)
Jan-04-22 04:01PM	Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma (GlobeNewswire)
Dec-14-21 08:53AM	Is Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Popular Amongst Institutions? (Simply Wall St.)
Dec-13-21 08:00AM	Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021 (GlobeNewswire) -7.25%
Dec-01-21 05:00PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.08%
Nov-15-21 08:00AM	Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting (GlobeNewswire)
Nov-09-21 05:00PM	Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-21 04:05PM	Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results (GlobeNewswire) +6.54%
Nov-03-21 05:00PM	Oncternal Therapeutics Joins Karolinska Institutets NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies (GlobeNewswire)
Nov-02-21 05:00PM	Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board (GlobeNewswire)
Nov-01-21 04:05PM	Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.45%
Oct-29-21 08:00AM	Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-27-21 03:03PM	Will Oncternal Therapeutics (ONCT) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-15-21 10:51AM	Companies Like Oncternal Therapeutics (NASDAQ:ONCT) Are In A Position To Invest In Growth (Simply Wall St.)
Oct-05-21 04:05PM	Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-01-21 04:01PM	Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-20-21 08:00AM	Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies (GlobeNewswire) -7.31%

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wills Robert James	Director	Apr 08 '24	Buy	8.96	3,086	27,655	10,000	Apr 10 08:38 PM
Wills Robert James	Director	Mar 28 '24	Buy	8.48	6,914	58,602	6,914	Apr 01 07:00 PM
HALE DAVID F	Director	Feb 23 '24	Buy	9.04	714	6,455	714	Feb 27 05:03 PM
HALE DAVID F	Director	Feb 23 '24	Buy	9.04	266	2,405	29,673	Feb 27 05:03 PM
Wills Robert James	Director	Feb 23 '24	Sale	9.04	980	8,859	0	Feb 27 05:02 PM
Kaufmann Gunnar F.	Chief Scientific Officer	Jun 14 '23	Buy	0.36	3,000	1,079	94,726	Jun 14 04:00 PM
Kaufmann Gunnar F.	Chief Scientific Officer	Jun 12 '23	Buy	0.35	25,000	8,745	91,726	Jun 14 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCT

Oncternal Therapeutics Inc

Upgrade your FINVIZ experience